Figure 3.

Mean days on sick leave and disability pension per 90‐day period in relation to day of randomization for randomized patients, end date of the run‐in period for nonrandomized methotrexate (MTX) responders as well as for their general population comparators (upper chart), and adjusted mean differences between infliximab plus MTX and conventional treatment (lower chart). Error bars indicate standard errors (upper chart) and 95% confidence intervals (lower chart). * = adjusted for work‐loss days the year before randomization. General population: comparators matched 5:1 by age, sex, education level, and place of residence; conventional treatment: sulfasalazine and hydroxychloroquine plus methotrexate; MTX responders: nonrandomized patients who had a favorable Disease Activity Score based on 28‐joint count response to MTX after the run‐in period.